TLR7 and cancer: The present study shows that the TLR7 agonist IMQ promotes autophagic cell death in melanoma cell lines and enhances radiosensitivity in an in vivo mouse melanoma model, and these effects are correlated with the anti-cancer immune response in tumor lesions.